Effectiveness and gastrointestinal tolerability during conversion and titration with once-daily OROS® hydromorphone extended release in opioid-tolerant patients with chronic low back pain
Martin E Hale,1 Srinivas R Nalamachu,2 Arif Khan,3 Michael Kutch4,* 1Gold Coast Research, LLC, Weston, FL, USA; 2International Clinical Research Institute, Overland Park, KS, USA; 3MedNorthwest Clinical Research Center, Bellevue, WA, USA; Duke University Medical Center, Durham, NC, USA; 4Applied Cli...
Main Authors: | Hale ME, Nalamachu SR, Khan A, Kutch M |
---|---|
Format: | Article |
Language: | English |
Published: |
Dove Medical Press
2013-05-01
|
Series: | Journal of Pain Research |
Online Access: | http://www.dovepress.com/effectiveness-and-gastrointestinal-tolerability-during-conversion-and--a12928 |
Similar Items
-
Repeat-dose steady-state pharmacokinetic evaluation of once-daily hydromorphone extended-release (OROS® hydromorphone ER) in patients with chronic pain
by: Vandenbossche J, et al.
Published: (2012-11-01) -
A new extended release formulation (OROS®) of hydromorphone in the management of pain
by: Sharon M Weinstein
Published: (2008-12-01) -
An open-label, 1-year extension study of the long-term safety and efficacy of once-daily OROS<sup>® </sup>hydromorphone in patients with chronic cancer pain
by: Tuca Alberto, et al.
Published: (2009-09-01) -
A Prospective Multicentre Study to Evaluate the Efficacy and Tolerability of Osmotic Release Oral System (Oros®) Hydromorphone in Opioid-Naive Cancer Patients: Results of the Korean South West Oncology Group Study
by: Eun-Kee Song, et al.
Published: (2015-01-01) -
Use of oral osmotic hydromorphone in opioid switch for cancer pain
by: Rosa Palomba, et al.
Published: (2008-09-01)